Article in Circulation. Genomic and precision medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
2 · The registry
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
5 · Who and what money
Authors and funding
26 authors.
Joyce N NjorogeDivision of Cardiology, Department of Medicine, Stanford University, Palo Alto, CA (J.N.N.).ORCID 0000-0003-4379-5328
Sandra Sanders van WijkDivision of Cardiology, Department of Medicine, Zuyderland Medical Center, Heerlen, the Netherlands (S.S.v.W.).ORCID 0000-0002-6291-6167
Thomas R AustinCardiovascular Health Research Unit, Departments of Epidemiology and Health Systems & Population Health (T.R.A., J.C.B., B.M.P.), University of Washington, Seattle.ORCID 0000-0003-2671-3706
Jennifer A BrodyCardiovascular Health Research Unit, Department of Medicine (J.A.B., B.M.P.), University of Washington, Seattle.ORCID 0000-0001-8509-148X
Colleen M SitlaniDepartment of Biostatistics (C.M.S., T.S., A.S.), University of Washington, Seattle.ORCID 0000-0001-7656-7482
Emily HamertonCardiology Section, San Francisco Veterans Affairs Health Care System & Department of Medicine (E.H., J.R.K.), University of California.
Joshua C BisCardiovascular Health Research Unit, Departments of Epidemiology and Health Systems & Population Health (T.R.A., J.C.B., B.M.P.), University of Washington, Seattle.ORCID 0000-0002-3409-1110
Albert HenryInstitute of Cardiovascular Science (A.H.), University College London, United Kingdom.ORCID 0000-0001-7422-2288
R Thomas LumbersInstitute of Health Informatics (A.H., R.T.L.), University College London, United Kingdom.ORCID 0000-0002-9077-4741
HERMES ConsortiumDepartment of Medicine, Brigham and Women's Hospital (The HERMES Consortium, Y.Y.), Harvard Medical School, Boston, MA.
Talia SeshaiahDepartment of Biostatistics (C.M.S., T.S., A.S.), University of Washington, Seattle.ORCID 0009-0006-3282-1956
Ali ShojaieDepartment of Biostatistics (C.M.S., T.S., A.S.), University of Washington, Seattle.ORCID 0000-0001-8846-3533
Yimin YangDepartment of Medicine, Brigham and Women's Hospital (The HERMES Consortium, Y.Y.), Harvard Medical School, Boston, MA.ORCID 0009-0002-6711-6123
Victoria LambersonDivision of Cardiovascular Medicine, Department of Medicine, University of Texas Southwestern Medical Center, Dallas (V.L., A.M.S.).ORCID 0000-0003-2760-5053
Bing YuDepartment of Epidemiology and Human Genetics Center, School of Public Health, University of Texas Health Science Center at Houston (B.Y.).ORCID 0000-0003-4818-1077
Amil M ShahDivision of Cardiovascular Medicine, Department of Medicine, University of Texas Southwestern Medical Center, Dallas (V.L., A.M.S.).ORCID 0000-0003-1056-4451
Nisha BansalDivision of Nephrology, Department of Medicine & Kidney Research Institute (N.B.), University of Washington, Seattle.ORCID 0000-0002-9583-8628
Sanjiv J ShahDivision of Cardiology, Department of Medicine, Northwestern University School of Medicine, Chicago, IL (S.J.S.).ORCID 0000-0002-5655-8201
Russell P TracyDepartment of Pathology and Laboratory Medicine, Larner College of Medicine, University of Vermont, Burlington (R.P.T.).ORCID 0000-0002-0080-2420
Robert E GersztenDivision of Cardiology, Department of Medicine, Beth Israel Deaconess Hospital (R.E.G.), Harvard Medical School, Boston, MA.ORCID 0000-0002-6767-7687
Lori L JenningsNovartis Institute for Biomedical Research, Cambridge, MA (L.L.J.).ORCID 0000-0001-5130-8417
Valborg GudmundsdottirUniversity of Iceland, Faculty of Medicine, Reykjavik (V. Gudmundsdottir, V. Gudnason, V.E.).ORCID 0000-0002-7459-1603
Vilmundur GudnasonUniversity of Iceland, Faculty of Medicine, Reykjavik (V. Gudmundsdottir, V. Gudnason, V.E.).ORCID 0000-0001-5696-0084
Valur EmilssonUniversity of Iceland, Faculty of Medicine, Reykjavik (V. Gudmundsdottir, V. Gudnason, V.E.).ORCID 0000-0001-9982-0524
Bruce M PsatyCardiovascular Health Research Unit, Departments of Epidemiology and Health Systems & Population Health (T.R.A., J.C.B., B.M.P.), University of Washington, Seattle.ORCID 0000-0002-7278-2190
Jorge R KizerCardiology Section, San Francisco Veterans Affairs Health Care System & Department of Medicine (E.H., J.R.K.), University of California.ORCID 0000-0001-9936-7803
Funding
Mapping the Progression to HFpEF in the Elderly through Longitudinal Changes in Cardiac FunctionR01HL135008 · NHLBI · UT SOUTHWESTERN MEDICAL CENTER · PI Amil M Shah · 2017 to 2026
$11.5M
Exceptional Survival: Trajectories to Functional Aging (CHS All Stars)R01AG023629 · NIA · UNIVERSITY OF PITTSBURGH AT PITTSBURGH · PI NEWMAN, ANNE B. · 2004 to 2016
$9.5M
CHARGE Consortium: Omics Discovery for CVD and Aging PhenotypesR01HL105756 · NHLBI · UNIVERSITY OF WASHINGTON · PI Bruce M Psaty, NICHOLAS L SMITH · 2011 to 2026
$9.5M
CARDIOVASCULAR HEALTH STUDY (CHS) - TASK AREA C, STUDY CLOSEOUT75N92021D00006 · NHLBI · UNIVERSITY OF WASHINGTON · PI PSATY, BRUCE · 2021 to 2024
$8.4M
CHS research resources for the cardiovascular health of older adultsU01HL130114 · NHLBI · UNIVERSITY OF WASHINGTON · PI BURKE, GREGORY L, KRONMAL, RICHARD A · 2016 to 2019
$6.6M
Plasma proteomics in CHS and population biologyR01HL144483 · NHLBI · UNIVERSITY OF WASHINGTON · PI DURDA, JON PETER, GERSZTEN, ROBERT E · 2019 to 2022
$6.0M
CHS Events Follow-up StudyU01HL080295 · NHLBI · UNIVERSITY OF WASHINGTON · PI PSATY, BRUCE M · 2005 to 2008
$4.6M
Quantifying cardiac structure and function to define the progression to hear failure in African AmericansR01HL143224 · NHLBI · UT SOUTHWESTERN MEDICAL CENTER · PI SHAH, AMIL M · 2018 to 2021
$3.4M
Proteomic signatures to identifypathways underlying the progression toheart failureR01HL148218 · NHLBI · UT SOUTHWESTERN MEDICAL CENTER · PI SHAH, AMIL M, YU, BING · 2020 to 2023
$3.4M
Discovery and Characterization of Rare Variant Effects in Dilated Cardiomyopathy via Large-Scale Biobank AnalysisR01HL167509 · NHLBI · VANDERBILT UNIVERSITY MEDICAL CENTER · PI Jennifer Below, Quinn Stanton Wells · 2023 to 2026
$2.8M
Infrastructure for mentored access to CHS data and specimensR01HL172803 · NHLBI · UNIVERSITY OF WASHINGTON · PI James S Floyd, Michelle Christina Odden · 2025 to 2026
$2.7M
Proteomic profiling to identify mechanisms of susceptibility and resilience to cardiac dysfunction in Black AmericansR01HL172495 · NHLBI · UT SOUTHWESTERN MEDICAL CENTER · PI James S Floyd, Michelle Christina Odden · 2025 to 2026
backgroundHeart failure (HF) and its main subtypes, heart failure with preserved ejection fraction (HFpEF) and heart failure with reduced ejection fraction (HFrEF), impose an enormous health burden on elders. Assessment of the circulating proteome to illuminate pathogenesis could open new opportunities for treatment.
methodsWe conducted a plasma proteomics screen of incident HF and its subtypes in 2 older population-based cohorts, the CHS (Cardiovascular Health Study) and the AGES-RS (Aging, Gene/Environment Susceptibility-Reykjavik Study). The 2 studies used SomaLogic platforms, with 4404 aptamers in common. Multivariable Cox models were fit to evaluate individual-protein associations with HF, HFpEF, and HFrEF separately in each cohort, and study-specific associations were combined by fixed-effects meta-analysis. Replication was performed in the ARIC (Atherosclerosis Risk in Communities) cohort. Two-sample Mendelian randomization of HF and its subtypes, along with colocalization analysis, was performed to support causal inference.
resultsAmong 8599 participants, 1590 experienced incident HF (536 HFpEF, 471 HFrEF). There were 119 proteins associated with HF, 15 proteins with HFpEF, and 11 proteins with HFrEF, at Bonferroni-corrected significance. Among these, 9 have never previously been identified for cardiovascular diseases, and another 61 represent new associations with incident HF or its subtypes. Of these 70 proteins, 55 of the 66 available replicated externally. Mendelian randomization analysis revealed 7 proteins genetically associated with HF at nominal significance; 2 were separately associated with HFpEF, and another 2 with HFrEF. Seven of these 9 proteins (NPDC1 [neural proliferation differentiation and control protein 1], APOF [apolipoprotein F], LMAN2 [lectin, mannose-binding 2], ADIPOQ [adiponectin], CD14 [cluster of differentiation 14], ARHGAP1 [Rho GTPase-activating protein 1], C9 [complement 9]) showed new, possibly causal associations, although we did not detect evidence for colocalization.
conclusionsIn this large-scale proteomic study involving 3 longitudinal cohorts of older adults, we identified and replicated 55 novel protein markers of HF or its subtypes, and 7 new, possibly causal proteins. These proteins may enhance risk prediction, improve understanding of pathobiology, and help prioritize targets for therapeutic development of these foremost disorders in elders.
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.
Large-Scale Proteomic Profiling of Incident Heart Failure and Its Subtypes in Older Adults. · full record | OpenQuestion